Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

A multicenter French study led by Rennes University Hospital reports potential benefits of glucagon-like peptide-1 receptor ...

Serena Williams has revealed that she's taking a GLP-1 injectable weight loss treatment, in addition to her health regimen.

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are ...

Serena Williams revealed how she turned her health around with the help of a GLP-1 medication after she struggled to lose ...

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise in reducing cancer risk among patients with obesity, particularly for endometrial, ovarian, and meningioma cancers.

This retrospective cohort study found that taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) was associated with a reduced overall risk of cancer, including lower risks of endometrial, ...

Longer-term studies will be needed to track whether per-patient costs might drop over time with continued use of the meds.

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 ...

Tennis legend Serena Williams has sparked conversations around fitness and health after reports of her weight loss journey ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...